Stonepine Capital Management LLC decreased its position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 20.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 390,000 shares of the biotechnology company’s stock after selling 102,265 shares during the period. Enanta Pharmaceuticals makes up approximately 10.8% of Stonepine Capital Management LLC’s holdings, making the stock its 2nd biggest position. Stonepine Capital Management LLC owned 2.04% of Enanta Pharmaceuticals worth $18,252,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ENTA. Dimensional Fund Advisors LP grew its position in Enanta Pharmaceuticals by 129.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after purchasing an additional 233,265 shares during the last quarter. State Street Corp boosted its holdings in shares of Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock valued at $23,063,000 after acquiring an additional 180,586 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 6.9% in the second quarter. Vanguard Group Inc. now owns 847,021 shares of the biotechnology company’s stock valued at $30,475,000 after acquiring an additional 54,856 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Enanta Pharmaceuticals by 9.3% in the second quarter. Renaissance Technologies LLC now owns 620,500 shares of the biotechnology company’s stock valued at $22,326,000 after acquiring an additional 52,807 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Enanta Pharmaceuticals by 180.8% in the first quarter. Bank of America Corp DE now owns 53,474 shares of the biotechnology company’s stock valued at $1,647,000 after acquiring an additional 34,429 shares in the last quarter. Hedge funds and other institutional investors own 66.91% of the company’s stock.

Shares of Enanta Pharmaceuticals Inc (ENTA) opened at $49.51 on Monday. Enanta Pharmaceuticals Inc has a one year low of $25.92 and a one year high of $50.92. The company has a market cap of $945.15, a P/E ratio of 56.26 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The business had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 491.3% on a year-over-year basis. research analysts anticipate that Enanta Pharmaceuticals Inc will post -1.57 EPS for the current fiscal year.

Several research analysts have recently issued reports on ENTA shares. Royal Bank Of Canada started coverage on shares of Enanta Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating for the company. JMP Securities increased their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 11th. Finally, Robert W. Baird increased their target price on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $46.25.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/enanta-pharmaceuticals-inc-enta-is-stonepine-capital-management-llcs-2nd-largest-position/1742392.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.